

Disclaimer

- The information contained in this confidential document ("Presentation") has been prepared by Grape King Bio (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.
- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers gives, has given or has authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision or supplement thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers takes any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness or injury of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation or the information.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved by the Company to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- This Presentation includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, general economic, market or business conditions and other unforeseen events. Prospective Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those is not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.

2



Investment Highlights



We are industry leader

capabilities

We are a leading health food manufacturer in Greater China, specializing in probiotics, mushroom and other herbal-based supplements. We command No. 1 position in probiotics and medicinal mushrooms supplements with 31% and 45% market share, respectively in 2019.


✓ We operate the second largest direct-selling company – Pro-Partner in Taiwan (2019 market share: 8.3%).

- We are one of the few health food companies in Taiwan that possess the capability to produce our own raw materials, manufacture products and distribute through own brands and channels.
 Strong R&D
 Our expertise in raw materials allow us to develop health supplements serving different benefits.
 - Our expertise in raw materials allow us to develop health supplements serving different benefits.
 Therefore, many of our products are TFDA approved for different health benefits.
 - ✓ We are also a frequent winner of major international conventions/competitions in respect to new product design/concept.



Solid growth with sustainable payout ratio

- ✓ We have delivered a solid earnings during 2008-2020 (CAGR of 19%/average ROE 25%).
- ✓ We have maintained more than 60% dividend payout in the past five years.
- ✓ On the back of a growing health and wellness market in Asia, we strive to deliver double digit topline growth through different growth catalysts from our individual business unit.



" **Company Overview :** Three core business units **2020 REVENUE** 9% 7% 1. Grape King Taiwan (Parent Co) Taiwan own brand & global OEM & ODM NTS Locus of all key ingredient design, formulation, and production for the whole Group. 9.2 bn 2. Pro-Partner (60%-own) **Taiwan direct selling distribution 2020 NET PROFIT** A differentiated distribution channel with products sold through direct-selling by members under the Pro-Partner brand. 19% 3. Grape King Shanghai (100%-own) NTS China OEM & ODM 1.3 bn Our manufacturing in China that focuses on OEM and ODM for domestic and global health food companies.

Grape King Taiwan Pro-Partner Grape King Shanghai









Competitive Strengths - State-of-the-Art Production Facilities




1. Grape King Taiwan

"



Taiwan - Grape King Brand Sales Channels





Our fourth best seller -Antrodia King 13% of 1H21 revenue 全面式護消 ^多壞的進不來 ばない 十年時前品牌 調整發育維持消化這種能 促進代謝,改變異處生態 30包入 Our third best seller -**Probiotics King** 14% of 1H21 revenue

Improves digestion and defecation

Liver protection and hangover prevention and alleviation

2. Pro-Partner



"

Pro-Partner Overview

4 key numbers of Pro-Partner

- Largest local direct selling company in Taiwan based on revenue.
- One of the fastest growing direct selling companies in Taiwan (15% sales CAGR from 2008 to 2020)


 Second largest overall direct selling company in Taiwan. (2019 market share: 8.3%)

35

Smallest product range – 35 Health and Beauty products among the top 5

• No. 41 in the worldwide direct selling company rankings for 2021

(Source: 2021 DSN Global 100- based on 2020 revenues)





Bai Yi Jie (toothpaste)

貝益潔

满效牙商

N.M.M.公 动波 木肥却Xylital 東化納

Grape King's Lactobacillus pentosus GK4

- → Inhibit 13 kinds of oral bacteria & Prevent cavities
- Xylitol → Anti-plaque
- Sodium fluoride
 → Prevent enamel erosion
- Mint → Sooth teeth

Hi Spray (oral spray)

• Grape King's Lactobacillus pentosus GK4

14: Spray Mas

→ Inhibit 13 kinds of oral bacteria & Prevent cavities

Life Spray ARAR

- Sorbitol
 - → Anti-plaque
- Thyme → Freshen breath
- Mint
 - \rightarrow Sooth teeth

How is Pro-Partner different from other direct selling companies?

85% of Pro-Partner's sales are contributed by old members



Executive distributor growth inline with membership growth

The growth rate of our executive distributors are similar to the growth rate of our members in the past years. This implies that our members are proportionally promoted each year based on their contribution to the group. However, due to Covid-19, our membership growth paused in 2020 as most of the training activities were restricted, nonetheless, our executive distributors continue to grow along with their contribution.



Pro-Partner membership growth rate

How is Pro-Partner different from other direct selling companies?


3. Grape King Shanghai



"

Grape King Shanghai Overview

- Established in 1993, Grape King Shanghai was initially targeted as the production base for Grape King's own brand products in China.
- A change in strategy steered by the new management to an OEM/ODM model has reversed several years of losses and turned the operation profitable.
- We see tremendous growth potential for Grape King Shanghai as it continues to acquire more ODM clients locally in China.



*In 2019, the overall demand was impacted by China government's tightening on direct-selling and healthcare industry & in 2020 the China consumption recovery has been softer-than-expected under the pandemic.





Our Vision

Our business tied to 5 megatrends; amplified by Covid



Urbanization and Globalization

Hygiene is a basic need and also the foundation of health of all mankind and societies





Rising conscious of a healthier lifestyle and personal well-being



Growing Ageing Society

Low birth rate and a growing ageing population




Digitalization

Digital is reshaping consumer behavior and shopping habits



Sustainability

Sustainability is a growing business priority, and even more so after Covid



Consumers' Experience is the Core of Everything We Do


Our Mission


"Cultivate and manufacture the best health-food supplements that are affordable to everyone.

Think Healthy, Think Grape King"

How?

- **Offer** scientifically-proven specialty products with competitive pricing
- **Create** lifestyle branding and storytelling based on personal experiences
- Leverage websites, e-commerce and digital marketing to drive customer excitement and loyalty
- **Deliver** customized experiences to encourage trial and repeat purchases






Powerful Brand Building

Capturing the distributors and consumers "mindshare" as the "go-to" brand for Liver Protection

Grape King Antrodia King (liver protection) Stress causes high blood pressure but also harms liver





Our Growth Strategies for Three Key Businesses

Key Objectives

Grape King Taiwan

Market share gain

12

03

- Expanding through new adjacencies
- Accelerate overseas ODM & raw materials businesses

Pro-Partner

- Unlock growth ceiling
- Improving demand forecast, sales visibility, and products time to market

Grape King Shanghai

- Clients diversification
- Prepping for the probiotics boom

Levers

- Market share gain through products upgrade and deeper channels penetration
- Business expansion through penetrating new product categories
- Continue to promote Grape King's raw material and R&D capabilities in probiotics and medicinal mushrooms.
- Accelerate new product launches from only 1-2 new products to 3-5 products per year.
- ✓ Focus on growing younger members.
- Duplicate Taiwan success in new geographies
- Cultivate 10 new customers with the potential of each contributing Rmb 10mn sales per annum
- ✓ Develop non-direct/WeChat customers
- Capture more business opportunities through local strategic partnerships and alliances

Sustainable topline and bottomline growth

Growing on Giant's Shoulder



Gur Joint Products with UPEC have recently been launched



Our Sustainability Progress



PURPOSE-LED BRAND



of our revenues are aligned with United Nation's (UN) Sustainable **Development Goals (SDGs)**

SASB

Adopted SASB indicators for ESG communications with investors

CLEANER PLANET

318 kg

of CO2e of carbon emission reduced in 2020

RE 100 100%

Of renewable energy usage by 2035 (15% by 2030)

Third-Party ESG **Credentials**



Top 5% among all TWSE companies in 2020 Corporate Governance Assessment



FAIRER SOCIETY

815 hrs

service hours were invested

in community investment

projects in 2020

NT\$1.6 mn

invested in employee

health management and

health promotion



2020

STRONGER STEWARDSHIP

33%

Of Board independence is expected in the coming Board election

42%

of female board members expected in the coming Board election, higher than TWSE average of 13.4%



Top 35% of all global companies, and the top scoring supplier of our **ODM** client




*Our Specialist Fermentation & Manufacturing Site (Zhongli plant) will relocated to Pinzhen Industrial Zone due to city development plan, expansion for PKL and different forms production line. The new plant construction is schedule to begin in the second half of 2020 with production expected to start in 2023. The relocation won't impact our operating and we expect that once the new facility is fully completed and 100% utilized, it is able to contribute additional NT\$10bn in revenue for Grape King.




" **Financial Highlights**

Historical revenue vs. operating profit




Historical EPS vs. ROCE






Note: The drop in gross margin is due to higher contribution from Shanghai Grape King with lower gross margin from ODM, but operating margin is around the same.



Historical cash dividend payout

Revenue Breakdown (2Q21 v.s. 2Q20)



1.Grape King Taiwan NT\$ 223mn (+47% YoY)


Thanks to strong sales of our own brand products as well as higher ODM revenues.

2.Pro-Partner NT\$ 1,966mn (+8% YoY)

Despite worsening pandemic in Taiwan, Pro-Partner was able to transition its members trainings and sales activities from offline to online.

3.Grape King Shanghai NT\$ 302mn (+15% YoY)

Thanks to improved orders from our major customers as China consumption continues to recover.





+5.1% YoY

+2.0% YoY

20%

1.Grape King Taiwan NT\$ 449mn (+46% YoY)


Thanks to strong sales of our own brand products as well as higher ODM revenues.

2.Pro-Partner NT\$ 3,563mn (flat YoY)

Pro-Partner's 2Q21 growth was offset by a lower 1Q21 due to extraordinary high base in 1Q20.

3.Grape King Shanghai NT\$ 464mn (+21% YoY)

China demand was severely impacted in 1H20 while the recovery was softer-thanexpected in 2H20



Grape King Taiwan Pro-Partner Grape King Shanghai

1H21 REVENUE

NTS

4.5 bn

1H21 NET PROFIT


NT\$


558 mn

9%

10%

10%







*Accounting principle changed to IFRS 15 from 2018, if excluding the impact from IFRS 15, Grape King Taiwan, Pro-Partner and Grape King Shanghai's revenue growth YoY were 11%, 3% and 51% in 2018.

" Five-Year Income Statement

| (NT\$ m) | 2016 | 2017 | 2018 | 2019 | 2020 | 1H21 | YoY (%) | | | | | |
|-----------------------------|---------|---------|---------|---------|---------|---------|---------|-------|--------|-------|--------|-------|
| | | | | | | | 2016 | 2017 | 2018 | 2019 | 2020 | 1H21 |
| Revenue | 9,185 | 9,388 | 9,183 | 9,239 | 9,168 | 4,476 | 26.7 | 2.2 | (2.2) | 0.6 | (0.8) | 5.1 |
| Gross Profit | 7,919 | 7,865 | 7,329 | 7,566 | 7,537 | 3,550 | 24.0 | (0.7) | (6.8) | 3.2 | (0.4) | 1.6 |
| Operating Expenses | (5,685) | (5,610) | (4,979) | (5,231) | (5,232) | (2,584) | 24.3 | (1.3) | (11.2) | 5.0 | 0.0 | 2.7 |
| Operating Profit | 2,234 | 2,254 | 2,350 | 2,335 | 2,305 | 966 | 23.3 | 0.9 | 4.2 | (0.6) | (1.3) | (1.2) |
| Non Operating Income/(Loss) | 78 | 151 | 77 | 105 | 73 | 41 | 11.8 | 92.6 | (49.2) | 36.8 | (30.2) | 12.9 |
| Pretax Income | 2,312 | 2,405 | 2,427 | 2,440 | 2,378 | 1,007 | 22.8 | 4.0 | 0.9 | 0.6 | (2.5) | (0.7) |
| Tax Expenses | (426) | (471) | (537) | (502) | (483) | (186) | 26.8 | 10.6 | 14.0 | (6.5) | (3.7) | (9.6) |
| Minority interest | (590) | (583) | (595) | (630) | (623) | (263) | 19.2 | (1.3) | 2.1 | 5.9 | (1.1) | 0.5 |
| Net Income to Parent | 1,297 | 1,352 | 1,295 | 1,309 | 1,272 | 558 | 23.3 | 4.3 | (4.2) | 1.1 | (2.8) | 2.0 |
| Basic EPS (NT\$) | 9.82 | 10.03 | 9.57 | 9.63 | 9.34 | 3.80 | 21.7 | 2.1 | (4.6) | 0.6 | (3.0) | (5.5) |
| Key Financial Ratios (%) | | | | | | | | | | | | |
| Gross Margin | 86.2 | 83.8 | 79.8 | 81.9 | 82.2 | 79.3 | | | | | | |
| Operating Expense Ratio | 61.9 | 59.8 | 54.2 | 56.6 | 57.1 | 57.7 | | | | | | |
| Operating Margin | 24.3 | 24.0 | 25.6 | 25.3 | 25.1 | 21.6 | | | | | | |
| Effect Tax Rate | 18.4 | 19.6 | 22.1 | 20.6 | 20.3 | 18.5 | | | | | | |
| Net Margin | 14.1 | 14.4 | 14.1 | 14.2 | 13.9 | 12.5 | | | | | | |

44

" Five-Year Balance Sheet

| (NT\$ m) | 2016 | 2017 | 2018 | 2019 | 2020 | 1H21 | YoY (%) | | | | | |
|--------------------------|--------|--------|--------|--------|--------|--------|---------|--------|--------|--------|-------|--------|
| | | | | | | | 2016 | 2017 | 2018 | 2019 | 2020 | 1H21 |
| Total Assets | 9,550 | 9,892 | 10,648 | 11,359 | 13,104 | 13,556 | 10.9 | 3.6 | 7.6 | 6.7 | 15.4 | 15.5 |
| Cash | 1,899 | 1,920 | 2,050 | 2,146 | 2,927 | 2,131 | 32.6 | 1.1 | 6.8 | 4.7 | 36.4 | 50.1 |
| AR & NR | 204 | 160 | 171 | 202 | 202 | 295 | 111.6 | (21.5) | 6.8 | 18.0 | (0.2) | 17.2 |
| Inventories | 435 | 492 | 563 | 546 | 689 | 751 | 21.0 | 13.1 | 14.4 | (2.9) | 26.2 | 13.3 |
| Fixed Assets | 6,084 | 6,355 | 5,927 | 6,454 | 7,308 | 7,190 | 8.7 | 4.5 | (6.7) | 8.9 | 13.2 | (2.5) |
| Total Liabilities | 3,767 | 3,564 | 3,715 | 3,888 | 5,126 | 3,315 | (14.3) | (5.4) | 4.2 | 4.7 | 31.8 | (32.7) |
| AP & NP | 198 | 323 | 262 | 223 | 255 | 353 | 29.6 | 63.2 | (18.9) | (15.1) | 14.7 | 31.5 |
| Total Borrowing | 1,206 | 1,022 | 1,119 | 1,177 | 1,921 | 213 | (50.6) | (15.2) | 9.5 | 5.2 | 63.3 | (82.2) |
| Total Equity | 5,783 | 6,328 | 6,933 | 7,471 | 7,978 | 10,241 | 37.1 | 9.4 | 9.6 | 7.8 | 6.8 | 50.5 |
| Key Financial Ratios (%) | | | | | | | | | | | | |
| A/R Turnover Days | 5.9 | 7.0 | 6.5 | 7.3 | 7.9 | 11.0 | | | | | | |
| Inventory Turnover Days | 113.0 | 109.5 | 102.4 | 119.3 | 136.4 | 137.4 | | | | | | |
| A/P Turnover Days | 49.9 | 61.6 | 56.8 | 52.2 | 52.7 | 60.4 | | | | | | |
| Cash Conversion Days | 69.0 | 54.9 | 52.1 | 74.4 | 91.6 | 88.0 | | | | | | |
| ROE (%) | 31.3 | 27.0 | 23.7 | 22.0 | 19.9 | 17.1 | | | | | | |
| ROA (%) | 14.3 | 13.9 | 12.6 | 11.9 | 10.4 | 10.1 | | | | | | |
| Net debt (cash)/Equity % | (12.0) | (14.2) | (13.4) | (13.0) | (12.6) | (18.7) | | | | | | |

45

Dividend Payout and Capex

| (NT\$ m) | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---------------|-------|-------|-------|-------|-------|-------|
| Net profit | 1,052 | 1,297 | 1,352 | 1,295 | 1,309 | 1,272 |
| Cash dividend | 730 | 862 | 903 | 883 | 884 | 948 |
| DPS (NT\$) | 5.6 | 6.4 | 6.7 | 6.5 | 6.5 | 6.4 |
| Payout ratio | 69.4% | 65.2% | 66.6% | 67.9% | 67.4% | 68.5% |
| Cash yield | 2.6% | 3.2% | 2.9% | 3.0% | 3.3% | 3.8% |
| Сарех | 2,635 | 736 | 772 | 1,116 | 630 | 1,214 |

Notes:

1. The big spike in capex in 2015-2017 is largely due to the investment of 1) Pro-Partner's new headquarter building, 2) the new factory and tourist factory in Pingzhen (Grape King Headquarter), 3) the new factory in Longtan (Grape King Bio-Tech Research Institute), and 4) additional production lines for Grape King Shanghai.

2. The capex for 2020 is mainly used for land acquisition for our Zhongli plant relocation and for new production facilities.

3. 2020 cash yield is calculated based on Grape King's 2021/6/2 closing share.





Appendix: Industry Trends

Confidential


Taiwan health food industry

Taiwan's health food industry is growing


Taiwan health food industry continues to be driven by consumers' increasing interest in healthier lifestyles as a cost-effective way to combat ageing and prevent modern illness.



We have been gaining market share in Taiwan's health food industry and we are also the industry leader in both mushroom-based supplements and probiotics.



Grape King's market share in Taiwan health food industry




48

Taiwan direct selling industry

Health food takes up ~60% of direct selling industry in Taiwan

According to Taiwan FTC, health food takes up 60% of the direct selling market share, which shows that direct selling is an important channel for health food products.



Taiwan direct selling industry is strictly regulated with entry barrier



Sales incentive system

- 1) Reasonable product price (mark-up on pricing);
- 2) Reasonable compensation structure (distribution of profit)

Member's system

According to Taiwan's regulation, it is illegal to produce earnings by simply introducing new participants instead of engaging in promotion & selling goods or services. Companies in violation may be subject to imprisonment and/or fines.

Pro-Partner is the only domestic direct selling company in Top 10

Top 10 players have high market concentration Pro-Partner has highest sales per product among top 3 players




China health food industry

China's health food industry grew 21% CAGR between 2011-2018

China's health food industry mainly driven by economic growth, disposable income, and rising health awareness. The industry has been growing for the past 7 years.

China direct selling has significant growth from 2011-2018

Direct selling has become an important distribution channel as sales from direct selling has grown from 26% in 2011 to 47% in 2018.








Despite the latest Administrative Measure of Health Food Registration and Filing having streamlined the certification process for vitamins and minerals, other products still need to go through the "Blue Hat" certification process by the CFDA.

China health food industry

Global probiotics market is still growing

According to Statista, global probiotics market has reached US\$40 bn with Asia Pacific region being the largest of all. The market is still increasing and is estimated to grow 7.0% CAGR between 2016-2022.



Grape King is the 7th largest distributor globally

We are ranked as the 7th largest probiotics supplement company globally, this also makes us the largest player in Greater China. Grape King is known for its capability in developing different strains of probiotics that target different health benefits.




China probiotics market

China probiotics market is expected to reach Rmb 85 bn in 2020

China's probiotic consumption remains at a relatively early stage and the supply is mostly dependent on import. According to ASKCI, China probiotics market is forecasted to reach RMB 85 bn dollars by 2020.

Taiwan and China probiotic supplement market are expected

According to Euromonitor, both Taiwan and China's probiotic supplement market are expected to deliver 27% and 23% of growth in 2016-2021, respectively.



Probiotics Supplements Retail Value (2016-2021)

